AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

✦ Arcellx and the Myeloma BetThin moat

Gilead Sciences (GILD) — the future bets

Gilead paid an implied $7.8 billion for Arcellx's anito-cel, a late entry into a myeloma market where Carvykti is growing 49% a year.

Gilead's largest bet of 2026 is on a cell therapy for multiple myeloma. It agreed on 23 February 2026 to buy Arcellx for $115 a share in cash plus a $5 contingent value right, an implied equity value of $7.8 billion1, and completed the deal on 28 April for about $6.4 billion of cash net of cash acquired2. It recorded $7.0 billion of acquired IPR&D for it3.

Gilead cell therapy sales and the Arcellx charge ($bn)1.87Cell therapy 20231.97Cell therapy 20241.84Cell therapy 20257.0Arcellx IPR&D 2026Gilead Form 10-K FY2025; Q2 2026 results release
The price is nearly four years of Kite revenue.

The prize is anito-cel, a CAR-T for relapsed or refractory multiple myeloma. Its Prescription Drug User Fee Act action date is 23 December 20264. The purchase gave Gilead full control of a programme it had shared with Arcellx since 2022, "Eliminating Profit-Share, Milestones, and Royalties"5. If approved, anito-cel will be sold by Kite, the cell therapy business Gilead bought for $11,155 million in 20176.

The bet is that Kite's manufacturing and sales organisation, built for Yescarta, can carry a second large product. Kite needs one: Gilead's cell therapy sales fell from $1,973 million in 2024 to $1,839 million in 20257 and were $417 million in the second quarter of 2026, down 14%8.

The obstacle is Johnson & Johnson's Carvykti, which already sells in multiple myeloma and grew 49.4% to $657 million in the second quarter9; the J&J page under Competitors covers the rivalry. Anito-cel will be a late entrant, which means it must be clearly better or more available to justify the price.

Gilead already knew the product well before it bought the company. The deal "Builds on Successful 2022 Collaboration on Anito-cel"10, and the FDA had accepted the biologics licence application for adults with relapsed or refractory multiple myeloma before the purchase was announced11. Gilead paid for control and full economics of a product it had already studied, which lowers the scientific risk and raises the price.

The arithmetic is unforgiving. At $7.0 billion of IPR&D, anito-cel needs to sell well over $1 billion a year to earn a return. If its sales in the first full year after approval are below $300 million, Gilead will have repeated its Immunomedics experience in cell therapy.

Moat trajectory: Widening

Anito-cel PDUFA date 23 December 2026.

The number that tests this moat
Reported
Kite cell therapy sales, full year
$1,839M (2025), from $1,973M in 2024; the Arcellx purchase added $7.0bn of acquired IPR&D

The franchise anito-cel must revive; first-year anito-cel sales below $300M would make Arcellx another Immunomedics.

Source: Gilead Sciences Form 10-K, FY2025 ↗
References
  1. ReportedIt agreed on 23 February 2026 to buy Arcellx for $115 a share in cash plus a $5 contingent value right, an implied equity value of $7.8 billion, and completed the deal on 28 April for about $6.4 billion of cash net of cash acquired.
    Gilead Sciences release of 23 February 2026, Form 8-K exhibit 99.1 - agreement to acquire Arcellx for $115 a share plus a $5 contingent value right, an implied equity value of $7.8 billion; anito-cel PDUFA date 23 December 2026. — February 2026 · publ. 23 February 2026 · source ↗
  2. ReportedIt agreed on 23 February 2026 to buy Arcellx for $115 a share in cash plus a $5 contingent value right, an implied equity value of $7.8 billion, and completed the deal on 28 April for about $6.4 billion of cash net of cash acquired.
    Gilead Sciences release of 28 April 2026, Form 8-K exhibit 99.1 - completion of the Arcellx acquisition for about $6.4 billion of cash net of cash acquired. — April 2026 · publ. 28 April 2026 · source ↗
  3. ReportedIt recorded $7.0 billion of acquired IPR&D for it.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - income statement, EPS, cash flow, balance sheet and 2026 guidance. — Q2 2026 · publ. 4 August 2026 · source ↗
  4. ReportedIts Prescription Drug User Fee Act action date is 23 December 2026.
    Gilead Sciences release of 23 February 2026, Form 8-K exhibit 99.1 - agreement to acquire Arcellx for $115 a share plus a $5 contingent value right, an implied equity value of $7.8 billion; anito-cel PDUFA date 23 December 2026. — February 2026 · publ. 23 February 2026 · source ↗
  5. ReportedThe purchase gave Gilead full control of a programme it had shared with Arcellx since 2022, "Eliminating Profit-Share, Milestones, and Royalties".
    Gilead Sciences release of 23 February 2026, Form 8-K exhibit 99.1 - agreement to acquire Arcellx for $115 a share plus a $5 contingent value right, an implied equity value of $7.8 billion; anito-cel PDUFA date 23 December 2026. — February 2026 · publ. 23 February 2026 · source ↗
  6. ReportedIf approved, anito-cel will be sold by Kite, the cell therapy business Gilead bought for $11,155 million in 2017.
    Gilead Sciences Form 10-K for 2018 - the Kite Pharma acquisition at $180 a share ($11,155 million) and product sales of Harvoni and Epclusa for 2016-2018. — FY2018 · publ. February 2019 · source ↗
  7. ReportedKite needs one: Gilead's cell therapy sales fell from $1,973 million in 2024 to $1,839 million in 2025 and were $417 million in the second quarter of 2026, down 14%.
    Gilead Sciences Form 10-K for 2025 - revenue by product, product group and region (Note 2) and the MD&A discussion of product sales. — FY2025 · publ. 24 February 2026 · source ↗
  8. ReportedKite needs one: Gilead's cell therapy sales fell from $1,973 million in 2024 to $1,839 million in 2025 and were $417 million in the second quarter of 2026, down 14%.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - revenue by product and product group and the drivers of each. — Q2 2026 · publ. 4 August 2026 · source ↗
  9. ReportedThe obstacle is Johnson & Johnson's Carvykti, which already sells in multiple myeloma and grew 49.4% to $657 million in the second quarter; the J&J page under Competitors covers the rivalry.
    Johnson & Johnson second-quarter 2026 sales schedules, Form 8-K exhibit 99.2 - Carvykti worldwide sales of $657 million, up 49.4%. — Q2 2026 · publ. July 2026 · source ↗
  10. ReportedThe deal "Builds on Successful 2022 Collaboration on Anito-cel", and the FDA had accepted the biologics licence application for adults with relapsed or refractory multiple myeloma before the purchase was announced.
    Gilead Sciences release of 23 February 2026, Form 8-K exhibit 99.1 - agreement to acquire Arcellx for $115 a share plus a $5 contingent value right, an implied equity value of $7.8 billion; anito-cel PDUFA date 23 December 2026. — February 2026 · publ. 23 February 2026 · source ↗
  11. ReportedThe deal "Builds on Successful 2022 Collaboration on Anito-cel", and the FDA had accepted the biologics licence application for adults with relapsed or refractory multiple myeloma before the purchase was announced.
    Gilead Sciences release of 23 February 2026, Form 8-K exhibit 99.1 - agreement to acquire Arcellx for $115 a share plus a $5 contingent value right, an implied equity value of $7.8 billion; anito-cel PDUFA date 23 December 2026. — February 2026 · publ. 23 February 2026 · source ↗
Sources
Generated October 4, 2026